XML 37 R25.htm IDEA: XBRL DOCUMENT
v3.26.1

Earnings Per Share | 6 Months Ended
--- | ---
Jun. 30, 2026
Earnings Per Share [Abstract] |
Earnings Per Share | Earnings Per Share Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The following table reflects the calculation of basic and diluted loss per common share (in thousands, except per share amounts):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2026 |  | 2025 |  | 2026 |  | 2025
Net loss per ImmunityBio common share – basic and diluted |  |  |  |  |  |  |
Numerator: |  |  |  |  |  |  |
Net loss attributable to ImmunityBio common stockholders | $ | (230,378) |  |  | $ | (92,555) |  |  | $ | (863,160) |  |  | $ | (222,201) |
Denominator: |  |  |  |  |  |  |
Weighted-average number of common shares outstanding – basic and diluted | 1,050,070 |  |  | 888,216 |  |  | 1,038,536 |  |  | 870,786 |
Net loss per ImmunityBio common share – basic and diluted | $ | (0.22) |  |  | $ | (0.10) |  |  | $ | (0.83) |  |  | $ | (0.26) |
Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted net loss per share. The following table details the number of shares of common stock underlying those securities that were excluded from the computation of weighted-average number of common shares outstanding – diluted (shares in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2026 |  | 2025 |  | 2026 |  | 2025
Related-party convertible note | 88,447 |  |  | 93,053 |  |  | 88,447 |  |  | 93,053 |
Outstanding third-party warrants | 47,862 |  |  | 35,424 |  |  | 47,862 |  |  | 35,424 |
Outstanding stock options | 23,559 |  |  | 25,931 |  |  | 23,559 |  |  | 25,931 |
Outstanding RSUs | 5,931 |  |  | 9,055 |  |  | 5,931 |  |  | 9,055 |
Outstanding related-party warrants | 1,638 |  |  | 1,638 |  |  | 1,638 |  |  | 1,638 |
Total | 167,437 |  |  | 165,101 |  |  | 167,437 |  |  | 165,101 |
The potentially dilutive securities shown in the table above exclude an option to purchase up to approximately $5.0 million of the company’s common stock pursuant to the SPOA entered in connection with the RIPA, as the exercise price cannot be determined until the date of exercise. See Note 10 “Revenue Interest Purchase Agreement” for more information.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 20 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration